logo
logo

Inxmed Raised $15 Million In Series B+ Financing To Advance Innovative Therapies To Drug-Resistant Cancers

May 09, 2022•about 3 years ago

Amount Raised

$15 Million

Round Type

series b

Description

InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Financing. The Series B+ was funded by Hyfinity Investments.

Company Information

Company

Inx Med

About

InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and being a China based biotech company with global impact. We have built translational medicine and clinical development team across Shanghai, Beijing, Nanjing, United States, Canada and Australia. We have built a highly differentiated pipeline and established partnership with various multinational pharmaceutical companies including Merck, Roche and Boehringer Ingelheim.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech